Lantheus Missed Expectations

Lantheus (LNTH) reported earnings of $1.48 per share on revenue of $372.76 million for the first quarter ended March 2025. The consensus earnings estimate was $1.65 per share on revenue of $379.21 million. The Earnings Whisper number was $1.70 per share. The company missed expectations by 12.94% while revenue grew 0.75% on a year-over-year basis.

The company said it expects 2025 non-GAAP earnings of $6.60 to $6.70 per share on revenue of $1.550 billion to $1.585 billion. The company's previous guidance was earnings of $7.00 to $7.20 per share on revenue of $1.545 billion to $1.610 billion and the current consensus earnings estimate is $7.04 per share on revenue of $1.59 billion for the year ending December 31, 2025.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions.